Acute Exacerbation of COPD (AECOPD) 

 Definition 

AECOPD = acute worsening of respiratory symptoms beyond normal day-to-day variation, leading to additional therapy.

It occurs in patients with underlying Chronic Obstructive Pulmonary Disease.

 Epidemiology & Importance

• Major cause of:
• ICU admissions
• Mechanical ventilation
• Mortality in COPD
• Frequent exacerbations → faster decline in FEV₁
• Mortality:
• Hospitalized AECOPD: ~5–10%
• ICU with MV: ~20–40%

Pathophysiology 

1. Trigger → Airway inflammation

• ↑ Neutrophils, macrophages
• ↑ Cytokines (IL-6, TNF-α)

2. Airway changes

• Bronchospasm
• Mucus hypersecretion
• Edema

3. Consequences

• ↑ Airway resistance
• Dynamic hyperinflation
• Air trapping

4. Gas exchange

• V/Q mismatch → hypoxemia
• Hypoventilation → hypercapnia
• Severe → respiratory acidosis

 Etiology 

 Clinical Features

Symptoms

• ↑ Dyspnea (most important)
• ↑ Sputum volume
• ↑ Sputum purulence
• Cough, wheeze

Signs

• Tachypnea, tachycardia
• Use of accessory muscles
• Prolonged expiration
• Cyanosis
• Altered sensorium → CO₂ narcosis

 Investigations 

Acute Exacerbation of COPD (AECOPD),“need for escalation” is what differentiates AECOPD from day-to-day variation

 WHEN COPD IS NOT PREVIOUSLY DIAGNOSED

You can still label as “suspected AECOPD” if:

• Typical history (smoker + chronic cough/dyspnea)
• Compatible clinical picture

 Confirm COPD later with spirometry:

• Post-bronchodilator FEV₁/FVC < 0.7

1. ABG (Cornerstone)

2. Imaging

• CXR:
• Exclude pneumonia, pneumothorax, heart failure
• CT (if unclear diagnosis)
• Bedside echo(Suspected HF / cor pulmonale-routine not recommended)

3. Lab tests

• CBC → infection(Leukocytosis → bacterial trigger)
• CRP / Procalcitonin → bacterial trigger
• Electrolytes → esp. K⁺(β₂-AGONISTS → HYPOKALEMIA,Acidosis → ↑K⁺)
• ECG → arrhythmias,RV strain (S1Q3T3) → PE

4. Microbiology

• Sputum culture (moderate-severe)-Guide antibiotic choice
• Viral panel (ICU)

 Differential Diagnosis (MUST EXCLUDE)

MANAGEMENT (GUIDELINE-BASED — GOLD / ERS / ATS)

 1. OXYGEN THERAPY (Target-driven)

• Target SpO₂: 88–92%
• Avoid over-oxygenation → CO₂ retention

Devices:

• Venturi mask (preferred)
• Nasal cannula (mild)

 2. BRONCHODILATORS(Best combination → SABA + SAMA)

First-line

• SABA: Salbutamol(Albuterol)

 Nebulization (preferred in severe cases)

• 2.5–5 mg every 20 min × 3 doses
• Then every 1–4 hr depending on response
• Duration of action : 4–6 hours

 MDI + spacer

• 4–8 puffs every 1–4 hr

SAMA: Ipratropium(Blocks M3 receptors → inhibits vagal bronchoconstriction)-Duration of action : 6–8 hours

Nebulization:-0.5 mg every 6–8 hr

MDI:-2–4 puffs every 6 hr

 4. LONG-ACTING BRONCHODILATORS (LABA / LAMA)

 NOT for acute relief

✔️ GOLD recommendation:

• Continue if patient already on them
• Restart before discharge

 Used for maintenance, not acute phase

 3. SYSTEMIC CORTICOSTEROIDS

• Prednisolone 40 mg PO once daily × 5 days

 WHY ONLY 5 DAYS? 

• Trials (e.g., REDUCE trial) showed:
• 5 days = 10–14 days (same efficacy)

Benefits:

• ↓ Treatment failure
• ↓ Hospital stay
• ↑ FEV₁ recovery

 If oral not possible:

• IV equivalent:
• Hydrocortisone 100 mg 6–8 hourly
• OR Methylprednisolone 40 mg/day

 Switch to oral as soon as feasible

NO taper required (if ≤5–7 days)

 ADVERSE EFFECTS -Short-term (relevant in AECOPD)

 4. ANTIBIOTICS 

✔️ GOLD INDICATIONS:

 A. Anthonisen criteria (classic)

Give antibiotics if:

• All 3 symptoms present:
1. Increased dyspnea
2. Increased sputum volume
3. Increased sputum purulence (MOST IMPORTANT)

 OR

• Any 2 symptoms + one must be purulence

 B. Severe exacerbation

• Mechanical ventilation (NIV or invasive)
• ICU admission

 C. Strong suspicion of bacterial infection

• Fever
• Leukocytosis
• Consolidation on imaging

 WHEN NOT TO GIVE

• Mild exacerbation without purulence
• Clearly viral illness
• No change in sputum

 Avoid overuse → resistance + adverse effects

 2. COMMON PATHOGENS

 Uncomplicated AECOPD:

• Haemophilus influenzae
• Streptococcus pneumoniae
• Moraxella catarrhalis

 Complicated / severe:

• Pseudomonas aeruginosa
• Enterobacteriaceae

 RISK FACTORS FOR PSEUDOMONAS 

• Severe COPD (FEV₁ < 50%)
• Frequent exacerbations
• Prior antibiotics / hospitalization
• Previous Pseudomonas isolation
• Bronchiectasis

Changes antibiotic choice significantly

3. ANTIBIOTIC CHOICE 

 A. UNCOMPLICATED AECOPD

 First-line options:

• Amoxicillin–clavulanate
• Macrolide (azithromycin, clarithromycin)
• Doxycycline

 B. COMPLICATED (NO PSEUDOMONAS RISK)

• Amoxicillin–clavulanate (preferred)
• Respiratory fluoroquinolone
• Levofloxacin
• Moxifloxacin

 C. PSEUDOMONAS RISK

• Piperacillin–tazobactam
• Cefepime
• Ceftazidime
• Meropenem (ICU)

 Tailor to local antibiogram

 4. DURATION OF THERAPY

 5–7 days (GOLD recommendation)

• Shorter courses preferred
• Longer only if:
• Severe infection
• Slow response

5.Mucolytic

 EVIDENCE (GOLD INTERPRETATION)

• Mixed evidence in acute setting
• No strong mortality or hospital outcome benefit
• Some benefit in:
• Sputum clearance
• Symptom relief

 Hence: NOT standard therapy

 6. VENTILATORY SUPPORT 

 Non-invasive ventilation (NIV) — FIRST LINE

Indications:

• pH < 7.35
• PaCO₂ > 45
• Severe dyspnea

Benefits:

• ↓ Intubation
• ↓ Mortality

 Invasive Mechanical Ventilation

Indications:

• NIV failure
• Cardiac arrest
• Severe acidosis (pH < 7.25)
• Altered mental status

 Ventilation Strategy in AECOPD

• Low RR (to avoid air trapping)
• High inspiratory flow
• Long expiratory time
• Permissive hypercapnia

 Complications

• Respiratory failure
• Pneumothorax
• Arrhythmias
• Secondary infections
• Ventilator-associated pneumonia

 Prognostic Indicators

 INDICATIONS FOR ICU ADMISSION

• Severe dyspnea with accessory muscles
• Persistent hypoxemia
• Severe acidosis
• Hemodynamic instability
• Altered consciousness

 DISCHARGE & SECONDARY PREVENTION

1. Pharmacological

• LABA + LAMA ± ICS
• Roflumilast (frequent exacerbators)

2. Non-pharmacological

• Smoking cessation
• Pulmonary rehab
• Vaccination:
• Influenza
• Pneumococcal

Recent Updates 

• Early NIV strongly recommended
• Short steroid course (5 days sufficient)
• Procalcitonin-guided antibiotics gaining role
• High-flow nasal oxygen (HFNO) emerging alternative in selected cases